Amifostine in clinical oncology: current use and future applications

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Anti-Cancer Drugs

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001813-200203000-00001PMID 11984063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil

  2004cited by this paper
• Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.

  2002cited by this paper
• A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer

  2001cited by this paper
• Long-term normal tissue effects of intraoperative electron radiation therapy (IOERT): late sequelae, tumor recurrence, and second malignancies.

  2001cited by this paper
• Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

  2001cited by this paper
• Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

  2001cited by this paper
• Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer.

  2001cited by this paper
• Cancer vascularization: implications in radiotherapy?

  2000cited by this paper
• Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.

  2000cited by this paper
• Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.

  2000cited by this paper
• ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non‐small cell lung cancer

  2000cited by this paper
• Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

  2000cited by this paper
• Protective effect of amifostine on dental health after radiotherapy of the head and neck.

  2000cited by this paper
• Amifostine can reduce mucosal damage after high‐dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study

  2000cited by this paper
• Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

  2000cited by this paper
• Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.

  2000influential reference
• The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors

  2000cited by this paper
• Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

  2000cited by this paper
• Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

  2000cited by this paper
• Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.

  2000cited by this paper
• Systemic inflammatory response syndrome associated with amifostine.

  2000cited by this paper
• A Phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207)

  2000cited by this paper
• Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer

  2000cited by this paper
• Colony stimulating factors in patients with fever and neutropenia.

  2000cited by this paper
• A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.

  2000cited by this paper
• Has the outlook improved for amifostine as a clinical radioprotector?

  2000cited by this paper
• Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines.

  2000cited by this paper
• Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.

  2000cited by this paper
• Docetaxel‐induced lymphopenia in patients with solid tumors

  2000cited by this paper
• Sparing of radiation-induced damage to the physis: fractionation alone compared to amifostine pretreatment.

  2000cited by this paper
• Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.

  1999cited by this paper
• Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.

  1999cited by this paper
• High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma

  1999cited by this paper
• Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

  1999cited by this paper
• Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma

  1999influential reference
• The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.

  1999cited by this paper
• Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer

  1999cited by this paper
• A new administration schedule for amifostine as a radioprotector in cancer therapy.

  1999cited by this paper
• American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

  1999cited by this paper
• Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.

  1999cited by this paper
• Erythropoietin for patients undergoing radiotherapy: a pilot study.

  1999cited by this paper
• High-dose leucovorin as sole therapy for methotrexate toxicity.

  1999cited by this paper
• Effects of Amifostine on Cisplatin Induced DNA Adduct Formation and Toxicity in Malignant Glioma and Normal Tissues in Rat

  1999cited by this paper
• Pharmacokinetics of amifostine: effects of dose and method of administration.

  1999cited by this paper
• Enhancement of tumor radioresponse in vivo by gemcitabine.

  1999cited by this paper
• Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?

  1999cited by this paper
• Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis.

  1999cited by this paper
• Daily Amifostine Given Concomitantly to Chemoradiation in Head and Neck Cancer

  1999cited by this paper
• Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.

  1999cited by this paper
• Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.

  1999cited by this paper
• Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients

  1998cited by this paper
• Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.

  1998cited by this paper
• The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase.

  1998cited by this paper
• Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.

  1998cited by this paper
• Fractionated carboplatin radiosensitization: a phase I dose-escalation study.

  1998cited by this paper
• Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.

  1998cited by this paper
• Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?

  1998cited by this paper
• Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.

  1998cited by this paper
• Amifostine: a radioprotector in locally advanced head and neck tumors.

  1998cited by this paper
• Radiochemotherapy with amifostine cytoprotection for head and neck cancer

  1998cited by this paper
• The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target

  1998cited by this paper
• Combined treatment of stage IV melanoma patients with amifostine and fotemustine — a pilot study

  1998cited by this paper
• A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report.

  1998cited by this paper
• Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors

  1997cited by this paper
• Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.

  1997cited by this paper
• Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: An interim report

  1997cited by this paper
• Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts

  1997cited by this paper
• Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.

  1997cited by this paper
• Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma.

  1997cited by this paper
• Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.

  1997cited by this paper
• Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.

  1997cited by this paper
• Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.

  1997cited by this paper
• Mitomycin C and Vinblastine in combination with Amifostine in metastatic breast cancer

  1997cited by this paper
• Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.

  1997cited by this paper
• The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion.

  1997cited by this paper
• Cytoprotective agents for anthracyclines.

  1996cited by this paper
• Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee.

  1996cited by this paper
• Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.

  1996cited by this paper
• Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer.

  1996cited by this paper
• Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.

  1996cited by this paper
• Amifostine does not alter the antitumor activity of cisplatin in a pre‐clinical model of testicular cancer

  1996cited by this paper
• Hypotensive Mechanisms of Amifostine

  1996cited by this paper
• WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells.

  1996cited by this paper
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.

  1996cited by this paper
• Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.

  1996cited by this paper
• Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.

  1996cited by this paper
• PP-3-8 Prognosis after salvage treatment for local-regional recurrence of mastectomy or breast conservation in eortic trial 10801

  1996cited by this paper
• Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.

  1995cited by this paper
• [Phase I study].

  1995cited by this paper
• Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

  1995cited by this paper
• Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

  1995cited by this paper
• A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.

  1995cited by this paper
• Topical application of WR-2721 achieves high concentrations in the rectal wall.

  1995cited by this paper
• Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.

  1994cited by this paper
• Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.

  1994cited by this paper
• Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N"-(dithiodi-2,1-ethanediyl)bis-1,3-propanediamine (WR-33278).

  1994cited by this paper
• Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.

  1994cited by this paper
• Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.

  1994cited by this paper

• Amino alkyl-alkyl/aryl sulphides (DRDE-07 and analogues) as promising cytoprotectants for sulphur and nitrogen mustards – A review

  2025cites this paper
• Amifostine-Iron Nanoparacrystalline for Tumor-Selective Immunogenic Ferroptosis.

  2025cites this paper
• Lepidium meyenii Walpers Promotes the Regeneration of Salivary Gland and Prevents Xerostomia After Irradiation Injury

  2025cites this paper
• Amifostine-loaded Prussian blue nanoparticles for simultaneous efficient radioprotection and deep decorporation of radiocesium.

  2025cites this paper
• Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches

  2024cites this paper
• Hearing loss during chemotherapy: prevalence, mechanisms, and protection.

  2024cites this paper
• Probiotic Consortia Protect the Intestine Against Radiation Injury by Improving Intestinal Epithelial Homeostasis.

  2024cites this paper
• Use of Drug Sensitisers to Improve Therapeutic Index in Cancer

  2024influential citation
• WR1065 conjugated to thiol-PEG polymers as novel anticancer prodrugs: broad spectrum efficacy, synergism, and drug resistance reversal

  2023cites this paper
• Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy—A Narrative Review

  2023cites this paper
• H2S-releasing adhesive hydrogel as oral radioprotectant for gastrointestinal tract radioprotection

  2023cites this paper
• A narrative review of radiation-related malignancy in the pelvis

  2021cites this paper
• Genoprotective Effect of Some Flavonoids against Genotoxic Damage Induced by X-rays In Vivo: Relationship between Structure and Activity

  2021cites this paper
• Oral Codelivery of WR-1065 Using Curcumin-Linked ROS-Sensitive Nanoparticles for Synergistic Radioprotection.

  2021cites this paper
• RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice

  2021cites this paper
• Lymphopenia and intratumoral lymphocytic balance in the era of cancer Immuno-Radiotherapy.

  2021cites this paper
• Oral mucositis: the hidden side of cancer therapy

  2020cites this paper
• Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice

  2020influential citation
• Green tea derivative (-)-epigallocatechin-3-gallate (EGCG) confers protection against ionizing radiation-induced intestinal epithelial cell death both in vitro and in vivo.

  2020cites this paper
• Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure

  2020cites this paper
• A Robust Methodology for the Synthesis of Phosphorothioates, Phosphinothioates and Phosphonothioates

  2020cites this paper
• The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury

  2020cites this paper
• Radioprotection and Radiomitigation: From the Bench to Clinical Practice

  2020cites this paper
• Radio-selective effects of a natural occurring muscle-derived dipeptide in A549 and normal cell lines

  2019cites this paper
• The efficacy and safety of amifostine for the acute radiation syndrome

  2019cites this paper
• The effects of radioprotectant and potential antioxidant agent amifostine on the structure and dynamics of DPPC and DPPG liposomes.

  2019cites this paper
• Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.

  2019cites this paper
• Advances in the Pharmacotherapy of Periodontal and Oral Mucosal Diseases

  2019cites this paper
• Cytoprotective Agents to avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.

  2019cites this paper
• A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis

  2018cites this paper
• Randomized double‐blind trial of amifostine versus placebo for radiation‐induced xerostomia in patients with head and neck cancer

  2018cites this paper
• SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy

  2018cites this paper
• Stratégie thérapeutique des neuropathies périphériques chimio-induites

  2018cites this paper
• Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage.

  2018cites this paper
• EXPRESSION OF THE INTESTINAL-TYPE ALKALINE PHOSPHATASE (IAPH) IN NORMAL AND MALIGNANT HUMAN TISSUES

  2018cites this paper
• AMIFOSTINE ( WR 2721 ) CONFERS DNA PROTECTION TO IN VIVO CISPLATIN-TREATED MURINE PERIPHERAL BLOOD LEUKOCYTES

  2017cites this paper
• Research and Development of Radioprotective Agents: A Mini-Review

  2017cites this paper
• Effects of yak-activated protein on hematopoiesis and related cytokines in radiation-induced injury in mice

  2017cites this paper
• Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells

  2017cites this paper
• Biological determinants of radioresistance and their remediation in pancreatic cancer.

  2017cites this paper
• Ameliorative efficacy of bioencapsulated Chironomous larvae with Shilajit on Zebrafish (Danio rerio) exposed to Ionizing radiation.

  2017cites this paper
• Two New Faces of Amifostine: Protector from DNA Damage in Normal Cells and Inhibitor of DNA Repair in Cancer Cells.

  2016cites this paper
• Improvement of the in vitro safety profile and cytoprotective efficacy of amifostine against chemotherapy by PEGylation strategy.

  2016cites this paper
• Structural and functional damages of whole body ionizing radiation on rat brain homogenate membranes and protective effect of amifostine

  2016cites this paper
• Acute Kidney Injury

  2015cites this paper
• Review of Optimization Methods for Cancer Chemotherapy Treatment Planning

  2015cites this paper
• γ-tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2

  2015cites this paper
• Protective Effect of Lycium ruthenicum Murr. Against Radiation Injury in Mice

  2015cites this paper
• Submandibular Gland Transfer for the Prevention of Postradiation Xerostomia in Patients with Head and Neck Cancer: A Systematic Review and Meta-Analysis

  2015cites this paper
• Mathematical Modeling of Immuno-radioprotector Delivery System Using a Monoclonal Antibody

  2015influential citation
• Amifostine enhances the antioxidant and hepatoprotective effects of UW and HTK preservation solutions.

  2014cites this paper
• Increased survival after irradiation followed by regeneration of bone marrow stromal cells with a novel thiol-based radioprotector

  2014cites this paper
• Normal tissue radioprotection by amifostine via Warburg-type effects

  2014cites this paper
• Effect of Amifostine in Head and Neck Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

  2014cites this paper
• WITHDRAWN: Addition of amifostine to CHOP regimen significantly reduced toxicity in patients with aggressive non-Hodgkin's lymphoma without affecting the long term survival: Results of a phase II trial.

  2013cites this paper
• Quercetin liposomes protect against radiation-induced pulmonary injury in a murine model

  2013cites this paper
• Dose Escalation of Amifostine for Radioprotection During Pelvic Accelerated Radiotherapy

  2013cites this paper
• Design and evaluation of biodegradable enteric microcapsules of amifostine for oral delivery.

  2013cites this paper
• The influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes

  2013cites this paper
• Amifostine-doxorubicin association causes long-term prepubertal spermatogonia DNA damage and early developmental arrest.

  2012cites this paper
• Amifostine Protects the White Cell Line Against Genotoxic Damage in Patients Undergoing Pelvic Radiotherapy

  2012cites this paper
• Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.

  2012cites this paper
• Acute Kidney Injury

  2012cites this paper
• Amifostine, a radioprotectant agent, protects rat brain tissue lipids against ionizing radiation induced damage: an FTIR microspectroscopic imaging study.

  2012cites this paper
• 阿米福汀在局部晚期非小细胞肺癌放疗中作用的meta分析

  2012cites this paper
• The Effect of Amifostine on Acute and Late Radiation Side Effects in Head and Neck Cancer Patients

  2012cites this paper
• The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance.

  2012cites this paper
• Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

  2012cites this paper
• Comparative study of the optimization theory for cancer treatment

  2011cites this paper
• Chemical genoprotection: reducing biological damage to as low as reasonably achievable levels.

  2011cites this paper
• 6 – Chemotherapy toxicities of the kidney

  2011cites this paper
• Amifostine-Related Fever-Rash During Fractionated Radiotherapy: Diagnostic and Predictive Role of C-Reactive Protein

  2011cites this paper
• L-Carnitine Protection Against Cisplatin Nephrotoxicity In Rats: Comparison with Amifostin Using Quantitative Renal Tc 99m DMSA Uptake

  2011cites this paper
• Renoprotective potency of amifostine in rat renal ischaemia-reperfusion.

  2010cites this paper
• Managing the patient presenting with xerostomia: a review

  2010cites this paper
• The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A

  2010influential citation
• Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma

  2010cites this paper
• Long-Term Complications in the Treatment of Nasopharyngeal Carcinoma

  2010cites this paper
• Computed Tomography Assessment of Lung Density in Patients With Lung Cancer Treated With Accelerated Hypofractionated Radio-Chemotherapy Supported With Amifostine

  2009cites this paper
• Amifostine (WR2721) Confers DNA Protection to in Vivo Cisplatin-Treated Murine Peripheral Blood Leukocytes

  2009cites this paper
• Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.

  2009cites this paper
• Radiation mitigation effect of cultured mushroom fungus Hirsutella Sinensis (CorImmune) isolated from a Chinese/Tibetan herbal preparation –Cordyceps Sinensis

  2008cites this paper
• Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation

  2008cites this paper
• Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging

  2008cites this paper
• Current trends in the management of oral mucositis related to cancer treatment.

  2008cites this paper
• Current concepts in the pathogenesis and management of oral mucositis as a complication of cancer therapy

  2008cites this paper
• Radiation Induced Lung Damage: Mechanisms and Clinical Implications

  2008cites this paper
• Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine

  2008cites this paper
• Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study

  2008cites this paper
• Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.

  2007cites this paper
• Medical and psychosocial issues in testicular cancer survivors

  2007cites this paper
• The effect of amifostine, a cytoprotective agent, on paraquat toxicity in mice

  2007influential citation
• Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.

  2007cites this paper
• Miscellaneous Functional Groups

  2007cites this paper
• Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1α

  2007cites this paper
• Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis

  2007cites this paper
• Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging

  2007cites this paper
• Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research.

  2006cites this paper
• Oral mucositis.

  2006cites this paper
• Effects of amifostin in prevention of cisplatin induced nephrotoxicity in rats

  2006cites this paper